Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 May 2004, Vol. 103, No. 10, pp. 3613-3614.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gross, T.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

IMMUNOBIOLOGY

SLAM "dunked"?

X-linked lymphoproliferative disease (XLP) is a rare immunodeficiency characterized by a diverse spectrum of manifestations, including fulminant infectious mononucleosis (FIM), lymphoma, and abnormal immunoglobulin synthesis, similar to common variable immunodeficiency (CVID).1 Although Epstein-Barr virus (EBV) infection is not necessary to manifest symptoms of XLP, the aberrant immune response to EBV is a major cause of morbidity and mortality in infected males.2 The defective protein is a very small (128 amino acids) cytoplasmic molecule consisting essentially of an src homology 2 (SH2) domain (96 amino acids).3 How this small, coadaptor protein can be responsible for such diversity and severity of clinical manifestations remains a mystery.

In the presence of a defective protein, the binding of SH2 domain–containing protein tyrosine phosphatase to signaling lymphocyte activation molecule (SLAM) or CD150 is unabated, which is hypothesized to result in uncontrolled phosphatase activity at the cell membrane and T-cell activation, and hence the name SLAM-associated protein, or SAP.3 Evidence to support this hypothesis comes from SAP knock-out mice, which develop a fulminant T-cell lymphoproliferative process with increased numbers of T helper 1 (Th1) cells and {gamma}-interferon ({gamma}-IFN) production following lymphocytic choriomeningitis virus infection, reminiscent of FIM of XLP patients.4


Sharifi and colleagues (page 3821) have for the first time studied in vitro the T-cell responses of 3 XLP males to various stimuli, including autologous EBV-transformed lymphoblastoid cell lines (EBV-LCLs). XLP cytotoxic T lymphocytes have decreased cytotoxic activity against EBV-LCLs compared with healthy controls. XLP T-cell lines were found to be phenotypically similar to healthy controls, but both XLP and control T cells have low expression of SLAM and high expression of 2B4 (CD244). Despite XLP T cells producing normal amounts of {gamma}-IFN in response to mitogen, CD28, CD3/CD28, SLAM, and CD3/SLAM, XLP T cells had decreased {gamma}-IFN production in response to 2B4, CD3/2B4, and EBV-LCLs. These results suggest that in humans 2B4/SAP interactions may be more important than SLAM/SAP in T-cell responses to EBV.

Another function of SAP appears to be in controlling or maintaining immunologic memory. There is growing evidence that memory responses, humoral and cellular, are impaired in SAP knock-out mice and XLP patients.5,6 Purtilo et al's first description of the disease noted the progressive nature of the immunodeficiency in XLP.1 This is another example of an "experiment of nature," where this small coadaptor molecule can have profound consequences (both immediate and long term) on the immune system's ability to respond adequately to EBV, probably other infections, and perhaps lymphoma. Sharifi et al have shown that T-cell responses to EBV can be restored by retroviral gene transfer of a normal SAP gene into deficient T cells. However, before therapeutic efforts can be undertaken safely, much more understanding of the regulation of this protein and its effect on immunologic responses are required.

--- Thomas Gross
Columbus Children's Hospital and Ohio State University

References

  1. Purtilo DT, Cassel CK, Yung JPS, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet. 1975;1: 935-941.[Medline] [Order article via Infotrieve]

  2. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations and the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96: 3118-3125.[Abstract/Free Full Text]

  3. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals through the co-receptor SLAM. Nature. 1998;395: 462-469.[CrossRef][Medline] [Order article via Infotrieve]

  4. Wu C, Nguyen KB, Pien GC, et al. SAP controls T cell response to virus and terminal differentiation of TH2 cells. Nat Immunol. 2001;2: 410-414.[Medline] [Order article via Infotrieve]

  5. Crotty S, Keresh EN, Cannons J, Schwartzberg PL, Ahmed R. SAP is required for generating long-term humoral immunity. Nature. 2003;421: 282-287.[CrossRef][Medline] [Order article via Infotrieve]

  6. Malbran A, Belmonte L, Ruibal-Ares B, et al. Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. Blood. 2004;103: 1625-1631.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease
Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter D. Arkwright, Christine Kinnon, Adrian J. Thrasher, and H. Bobby Gaspar
Blood 2004 103: 3821-3827. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gross, T.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020